|
OCTOBER'S BEST FEATURED EDITORIAL |
|
|
Government Contract Advances Walgreens In Clinical Space | By Dan Schell, chief editor, Clinical Leader | Walgreen’s new $25 million deal with BARDA (Biomedical Advanced Research and Development Authority) is a huge win for the pharmacy chain. John Campbell, head of DCTs at Walgreens, explains the ins and outs of the study and what could be next for the company regarding its clinical trials division. |
|
|
|
CUP Benefits And Strategies In Rare Disease | By Davelyn Eaves Hood, head of medical & patient affairs, Rezolute, and Ana Tediosi, head of expanded access program strategy, WEP Clinical | In part two of this series, Rezolute discusses the benefits of continuing patient care with a compassionate use program (CUP) and shares best practices for implementing one. |
|
|
OCTOBER'S BEST INDUSTRY INSIGHTS |
|
|
A Strategic Framework For Positive Site-Sponsor Relationships | By Matthew Jones and Julia Scanlon, IQVIA Technologies | Through an examination of evolving trial strategies and implementation, we aim to lay the groundwork for a collaborative, mutually beneficial atmosphere, ultimately leading to a sustainable competitive edge. |
|
|
|
Choosing A Central Lab For Clinical Trials | By Cerba Research | Choosing the right central lab is critical for ensuring efficient and dependable clinical trial results, but what are the key factors to consider when selecting a central lab partner? |
|
|
|
|
|
|
| Connect With Clinical Leader: |
|
|
|
